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Fig 1. Trigeminal trophic syndrome. Left facial erosions,
scarring, and ulceration of the tragus.
Fig 2. Axial T1-weighted magnetic resonance imaging of
the brain. Left- and right-sided meningiomas (black
arrowheads) and trigeminal nerves (white arrowheads).
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Trigeminal trophic syndrome secondary to
recurrent meningioma
To the Editor: A 45-year-old man with a history of
childhood acute lymphocytic leukemia and
radiation-induced bilateral recurrent meningiomas
requiring resection in 2001 and resection and
Gamma-Knife in 2010 presented with a 4-week
history of unexplained facial ulcerations followed
by the development of headaches. He reported
waking with ‘‘bloody lesions’’ on his face, which
were preceded by facial pain he rated on a scale of 1
to 10 as an 8. He denied pruritus and picking his face.
His headaches were associatedwith left-sided photo-
phobia and facial numbness. Physical exam revealed
a red, ulcerated, indurated left tragus. Scattered 5- to
10-mm annular pink atrophic scars with peripheral
hyperpigmentation were seen on the left cheek,
forehead, and nose (Fig 1). A 2- x 1-cm superficial
ulceration within a well-healed surgical scar and a
1.2-cm x 6-mm crescentic superficial ulceration on
the left lateral nose were noted. Dried blood was
noted under his fingernails. Neurologic exam re-
vealed diminished sensation to touch, pinprick, and
temperature on the left side of the face.
Complete blood count with differential, complete
metabolic profile, and liver function tests were
normal. Skin biopsy of the left tragus showed normal
skin without evidence of malignancy or significant
inflammation. Brain magnetic resonance imaging
study showed a left middle cranial fossa meningioma
with interval enlargement compared with the
previous year with involvement of the ipsilateral
trigeminal nerve (Fig 2). A right posterior clinoid
meningioma, unchanged from the previous study,
Open access under CC BY-NC-ND license.was also present. Trigeminal trophic syndrome (TTS)
involving all 3 branches of the trigeminal nerve was
diagnosed.
TTS, also called trigeminal neurotrophic
ulceration, is a rare condition occurring after damage
to the trigeminal nerve and presents with unilateral
anesthesia with crescentic ulceration classically
involving the ala nasi. Ulceration is self-induced
secondary to paresthesias and patients are often
unaware of self-mutilation. Causes of trigeminal
nerve damage leading to TTS include trigeminal
ablation, infarction, vertebrobasilar insufficiency,
acoustic neuroma, astrocytoma, meningioma, spinal
cord degeneration, Mycobacterium leprae neuritis,
herpes zoster, syringobulbia, postencephalitic
parkinsonism, and trauma.1
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second trigeminal division dermatome, followed by
the first and third.2 One case of TTS involving all
3 branches of the trigeminal nerve in the context
of surgical resection for meningioma has been
reported.3 Another report described a patient in
whom trigeminal sensory dysfunction developed 1
year after meningioma excision and subsequently
ala nasi ulceration developed 6 weeks after a third
surgery.4
Trigeminal dysfunction causing facial numbness
was reported in 11% of patients who underwent
surgery for cranial base meningiomas.5 Nerve
injury was attributed in some patients to intra-
operative dissection within the cavernous sinus,
tumor infiltration, or gross injury to the nerve
distal to the cavernous sinus; 42% of patients had
no identifiable cause. We report a case of TTS
involving V1-V3 related to a recurrent meningi-
oma. Although our patient had a history of surgical
resection and Gamma-Knife therapy, which could
have caused trigeminal nerve damage, the associ-
ation with additional neurologic symptoms and
the evidence visualized on neuroradiologic imag-
ing suggest recurrent disease as the etiology of the
TTS. Interestingly, the appearance of skin lesions
preceded the development of headaches, suggest-
ing that TTS can indicate neurologic disease
before the development of other neurologic
symptoms.
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refractory cutaneous sarcoidosis
To the Editor: Sarcoidosis, a multisystemic granulo-
matous disease of unknown etiology, involves the
skin in about 25% of cases.1 We describe leflunomide
efficacy in 2 patients whose cutaneous sarcoidoses
were refractory to conventional therapies.
Patient 1 was a 46-year-old woman with lung
(stage 1), skin, and nasosinusal sarcoidosis lasting
16 years. Her medical history included hypertension
and thalidomide-induced lower limb neuropathy.
Skin lesions were resistant to topical steroids,
tacrolimus, hydroxychloroquine, thalidomide, and
methotrexate; the patient refused oral prednisone.
Leflunomide (20 mg/day) was started alone because
she had progressive nasosinusal involvement and
cutaneous lesions on her limbs and buttocks, and a
large patch on her right cheek (Fig 1, A).
Angiotensin-converting enzyme (ACE) level was
84 (normal \41 IU/mL). Dramatic cutaneous
improvement was noted at 6 months, and complete
remission (CR) of cutaneous (Fig 1, B) and
nasosinusal lesions was obtained after 1 year of
leflunomide therapy as shown by normal ACE level
and normal control skin biopsy of the left arm.
Because sarcoid joint manifestations occurred
whenever the leflunomide dose was decreased to
less than 10 mg/day, maintenance therapy with that
dose was pursued without any relapse after 34
months. Vulvar and cervical intraepithelial neopla-
sias, diagnosed after 24 months, were treated with
surgical excision and cervical conization, respec-
tively, without recurrence 1 year later.
Patient 2, a 51-year-old woman with type 1
diabetes and hypertension had stage 1 lung and
nasosinusal sarcoidosis and severe facial lupus
pernio (Fig 2, A) lasting 9 years that was resistant to
topical and systemic corticosteroids, thalidomide,
infliximab, etanercept, efalizumab, methotrexate
alone, methotrexate combined with hydroxychlor-
oquine, and intralesional corticosteroid injections.
Leflunomide (20 mg/day) was added to a stable
methotrexate dose (20 mg/wk). Striking regression
of skin lesions and nasosinusal symptoms was
obtained after 4 months of leflunomide therapy
(Fig 2, B). Discontinuing methotrexate and
